吡格列酮对无胰岛素抵抗的原发性高血压患者左心室肥厚及炎性因子的影响

Effects of Pioglitazone on Left Ventricular Hypertrophy and Inflammatory Factors in Primary Hypertension Patients without Insulin Resistance

目的探讨吡格列酮对无胰岛素抵抗的原发性高血压患者左心室肥厚及炎性因子的影响。方法选择无胰岛素抵抗的原发性高血压伴左心室肥厚患者60例,随机分成吡格列酮组与常规治疗组。常规治疗组给予依那普利治疗,吡格列酮组给予依那普利和吡格列酮治疗,均治疗6个月。比较两组患者治疗前后左心室质量指数(LVMI)、血清肿瘤坏死因子α(TNF-α)、白介素1β(IL-1β)和白介素6(IL-6)的变化水平。结果吡格列酮组与常规治疗组患者治疗前LVMI、血清TNF-α、IL-1β、IL-6的水平比较,差异均无统计学意义(P>0.05),两组患者治疗后LVMI、血清TNF-α、IL-1β、IL-6的水平比较,差异均有统计学意义(P<0.05)。结论吡格列酮能通过抗炎作用逆转原发性高血压左心室肥厚。

Objective To investigate the effect of Pioglitazone on left ventricular hypertrophy and inflammatory factors in patients with primary hypertension and without insulin resistance.Methods Totally 60 primary hypertension patients without insulin resistance were randomly divided as trial group and control group.The patients in the control group were treated with Enalapril,while those in the trial group with Enalapril plus Pioglitazone for 6 months.The changes of left ventricular mass index （LVMI）,serum tumor necrosis factor-α （TNF-α）,interleukin-1β （IL-1β） and interleukin-6 （IL-6） were compared between the two groups before and after treatment.Results There was no significant difference between the two groups in levels of LVMI,serum TNF-α,IL-1β,and IL-6 decreased before the treatment（P〈0.05）;however,after the treatment there were （P〈0.05）.Conclusion Pioglitazone can reverse left ventricular hypertrophy in primary hypertension by its anti-inflammatory action.